Replies to post #57820 on Biotech Values

[iwfal]

Dew - Earlier this week I said I would be trying to understand the coagulation pathways, but now having done some research it looks very much like it is not a well understood system. We may know many of the component players in the pathways, but we don't really understand all the feedback loops nor why, in aggregate, the system works the way it does - e.g. Factor V Leiden polymorphism appears to have a significant effect on excess clotting in veins, but not in arteries. But no real idea why.

Do you have best site (or book) that explains such things as which factors play the most important role in different situations or which drugs in which situations and why?

[DewDiligence]

ANTICOAGULANT INDEX

[Added PR on Lancet study and
updates on various drug candidates.]

General
#msg-25160571 Anticoagulant market has large potential (WSJ)
#msg-25985612 Anticoagulant market has large potential (graphic)
#msg-18759853 Overview of the new oral anticoagulants
#msg-26451612 Venous thromboembolism is a big, big problem (The Lancet)

M118
#msg-24457684 M118 has blockbuster potential
#msg-23604134 MNTA starts phase-2 in ACS
#msg-19617749 Start of phase-1 using sub-Q formulation
#msg-25147975 M118 vs oral FXa inhibitors

Rivaroxaban
#msg-25147464 Rivaroxaban bests Lovenox in VTE prevention
#msg-24337258 Bayer plans 50,000(!)-patient study

Apixaban
#msg-19134406 PFE, BMY ink $1B collaboration
#msg-21044973 Apixaban non-inferior to Warfarin in phase-2

Dabigatran
#msg-26086079 BI completes enrollment of huge AF trial
#msg-25152872 BI starts phase-2 in ACS
#msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention

Miscellaneous
#msg-26298260 Biotinylated Idraparinux causes excess bleeding in AF
#msg-22938795 Status of SNY’s SR123781, AVE5026, and Otamixaban
#msg-10569101 Arixtra bests Lovenox in ACS
#msg-26385806 NUVO’s NU172 starts phase-1